Frank Watanabe

President and CEO

Mr. Watanabe has been the President of Arcutis since 2016, and Chief Executive Officer since 2017. Prior to joining Arcutis, he was co-founder and Chief Operating Officer of Kanan Therapeutics, a cardiovascular drug development company, and before that, was Vice President of Strategy and Corporate Development at Kythera Biopharmaceuticals.

Mr. Watanabe was an executive at Amgen, Inc. from 2005 to 2013, where he was involved in the development of Repatha® for hyperlipidemia and Aimovig® for migraine, and worked on the U.S. marketing of Enbrel® in both dermatology and rheumatology. Previously, he was an executive with Eli Lilly and company, and an official in the U.S. Government. He was also a commissioned officer in the U.S. Navy Reserves for 25 years. He currently serves on the board of Amunix Pharmaceuticals. Mr. Watanabe earned his M.A. in National Security Studies, and his B.A. in International Relations, both at Georgetown University.